System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to EGFR (Phospho-Tyr1173)

EM-13 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-575-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-575-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


The oncoprotein EGFR (epidermal growth factor receptor), also known as HER1 / ErbB1, is a member of ErbB family of cell surface receptor tyrosine kinases. This 170 kDa transmembrane glycoprotein is often associated with cancerogenesis, although its activation state is controlled at various levels including trafficking and degradation steps. Binding of receptor-specific ligands to the EGFR ectodomain results in formation of homodimeric or heterodimeric kinase-active complexes into which HER2 / ErbB2 is recruited as a preferred partner. Subsequent signaling cascades such as RAS/MAPK and PI3K/AKT pathways lead to cell proliferation and survival responses.


The antibody EM-13 reacts with human EGFR (ErbB1 / HER1) phosphorylated on tyrosine 1173.

Regulatory Status


Synthetic phospho-peptide covering sequence around tyrosine 1173 of human EGFR.

Species Reactivity:

  • Human

Negative Species:


  • Flow Cytometry
  • Immunoprecipitation
  • Western Blotting
    Recommended dilution: 1 μg/ml
    Positive control: EGF-stimulated A431
    Negative control: Non-stimulated A431
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001 Dec 15;61(24):8887-95. [Abstract] [Full Text]
  • *Batzer AG, Blaikie P, Nelson K, Schlessinger J, Margolis B: The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor. Mol Cell Biol. 1995 Aug;15(8):4403-9. [Abstract] [Full Text]
  • *Daniele T, Di Tullio G, Santoro M, Turacchio G, De Matteis MA: ARAP1 regulates EGF receptor trafficking and signalling. Traffic. 2008 Dec;9(12):2221-35. [Abstract]
  • *Rappl A, Piontek G, Schlegel J: EGFR-dependent migration of glial cells is mediated by reorganisation of N-cadherin. J Cell Sci. 2008 Dec 15;121(Pt 24):4089-97. [Abstract]
  • *Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE. 2009;4(2):e4576. [Abstract] [Full Text]
  • *Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs SS, Dempsey PJ, Peek RM Jr, Cover TL, Washington MK, Wilson KT, Polk DB: Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology. 2009 Apr;136(4):1297-1307, e1-3. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG1 Isotype Control
  • Example Data

    Fig. 1.

    Fig. 1. Western blotting analysis of EGFR (phospho-Tyr1173) by mouse monoclonal antibody EM-13 in EGF-treated A431 (A), CALU-3 (B), MCF-7 (C), Jurkat (D) and Ramos (E) cell lines (reducing conditions). 


    Fig. 2.

    Fig. 2. Immunoprecipitation of EGFR from EGF-treated A431 cells by monoclonal antibodies EM-12 (A), EM-13 (B), a commercial anti-EGFR polyclonal antibody (C) and anti-EGFR monoclonal mAb108 (D). The precipitates were immunoblotted with EM-12 or EM-13 antibody, and goat anti-mouse-HRP.  


    Fig. 3.

    Fig. 3. Immunoprecipitation of EGFR from EGF-treated A431 cells by phosphospecific monoclonal antibodies EM-12 (A), EM-13 (B), a commercial anti-EGFR polyclonal antibody (C) and anti-EGFR monoclonal mAb108 (D). The precipitates were immunoblotted with a commercial anti-EGFR polyclonal and goat anti-rabbit-HRP.   

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy